I attended National Health IT Week in Washington DC. There were a number of seminars and meetings focused on the growth of health IT in the United States.
Regardless of the healthcare setting, the “reason for use” for a medication is essential to evaluating a prescription or drug order. With the growth of electronic health records, computerized physician order entry and electronically transmitted prescriptions, it would seem that associating a drug indication with each prescription is finally feasible.
Despite their many similarities as regulated medical products, drugs and medical devices have for years presented stark differences in how people obtain information about them. All that is changing, though. With the commencement of required Unique Device Identifier (UDI) listings in 2014 – think of UDIs as the NDCs for devices – medical devices are now headed down the path blazed by drugs.
A recent article in The New York Times on the food industry’s search for natural food dyes, “Brand New Hue,” prompted a fair question: why are artificial colorants added to drugs? For they are, in abundance.
At the Health 2.0 Conference last month, budding Health IT entrepreneurs gathered for a Code-A-Thon. Learn more from the winners and how they used the FDB Cloud Connector to make it happen.
Dewey Howell, MD, VP of Clinical Applications provides his take on e-prescribing’s progress and potential.
Be notified about new FDB Blog posts as they are published by submitting the information below. (If you are already an FDB Customer in North America, you are automatically receiving blog updates by email and do not need to sign up.)
Senior VP and Editorial Director
Associate Product Manager
Howell, MD, PhD
VP, Clinical Applications
VP, Health Policy